ArticleAdvances in laboratory medicine2026
Anti-GBM pulmonary-renal syndrome: when the laboratory makes the difference.
Article in Advances in laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Pulmonary-renal syndrome (PRS) is a serious condition characterized by concurrent alveolar hemorrhage and rapidly progressive glomerulonephritis. One of the potential causes of PRS is the presence of anti-glomerular basement membrane (anti-GBM) antibodies, which may induce Goodpasture syndrome, a rare, albeit life-threatening, condition associated with a high mortality. Case presentation: We report the case of a 31 year-old male patient with Huntington's disease who presented with dyspnea, a dry cough, and asthenia. Urgent laboratory tests demonstrated severe anemia, acute kidney failure, and additional laboratory abnormalities consistent with vasculitis. Chest CT scan revealed diffuse alveolar hemorrhage. The autoimmune panel was anti-GBM positive, thereby leading to diagnosis of Goodpasture syndrome. Conclusions: Goodpasture syndrome is a form of pulmonary-renal syndrome that requires prompt diagnosis and intensive immunosuppressive therapy. Patients may follow a severe course and progress into end-stage renal disease. Early detection of anti-GBM antibodies is essential for diagnosis. The clinical laboratory plays a major role in supporting therapeutic decision-making and treatment response monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.